1,937.20
+3.00
+(0.16%)
At close: April 17 at 3:30:02 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
215,250,200
196,563,400
162,699,800
161,927,900
149,269,900
Cost of Revenue
72,332,000
71,467,800
72,648,900
70,880,500
59,165,500
Gross Profit
142,918,200
125,095,600
90,050,900
91,047,400
90,104,400
Operating Expense
54,130,300
97,129,200
81,156,500
85,541,400
72,711,900
Operating Income
88,787,900
27,966,400
8,894,400
5,506,000
17,392,500
Net Non Operating Interest Income Expense
-2,308,300
-2,653,800
-2,418,700
-1,099,600
-808,000
Pretax Income
36,168,700
24,222,700
7,164,900
-13,722,100
16,764,500
Tax Provision
7,247,700
4,867,000
2,688,000
1,371,500
4,485,200
Net Income Common Stockholders
28,685,300
19,144,800
4,300,800
-15,280,400
12,165,300
Diluted NI Available to Com Stockholders
28,685,300
19,144,800
4,300,800
-15,280,400
12,165,300
Basic EPS
62.90
42.05
9.46
-33.65
26.84
Diluted EPS
62.70
41.87
9.41
-33.65
26.72
Basic Average Shares
455,946.95
455,240.46
454,692.96
454,042.89
453,280.61
Diluted Average Shares
457,487.61
457,226
456,946.99
455,240.30
455,236.63
Rent Expense Supplemental
--
696,900
702,700
680,800
671,700
Total Expenses
126,462,300
168,597,000
153,805,400
156,421,900
131,877,400
Net Income from Continuing & Discontinued Operation
28,685,300
19,144,800
4,300,800
-15,280,400
12,165,300
Normalized Income
30,703,765.70
20,485,004.85
4,393,963.31
-1,597,850
11,535,239.23
Interest Income
--
462,300
324,300
328,100
598,400
Interest Expense
2,444,900
2,790,400
2,402,100
1,072,600
1,174,800
Net Interest Income
-2,308,300
-2,653,800
-2,418,700
-1,099,600
-808,000
EBIT
38,613,600
27,013,100
9,567,000
-12,649,500
17,939,300
EBITDA
50,945,400
38,981,200
18,373,900
3,937,600
26,813,400
Reconciled Cost of Revenue
72,332,000
71,467,800
72,648,900
70,880,500
59,165,500
Reconciled Depreciation
12,331,800
9,955,600
8,806,900
16,587,100
8,874,100
Net Income from Continuing Operation Net Minority Interest
28,685,300
19,144,800
4,300,800
-15,280,400
12,165,300
Total Unusual Items Excluding Goodwill
-2,524,300
-1,677,200
-149,100
-19,546,500
860,200
Total Unusual Items
-2,524,300
-1,677,200
-149,100
-19,546,500
860,200
Normalized EBITDA
53,469,700
40,658,400
18,523,000
23,484,100
25,953,200
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-505,834.30
-336,995.15
-55,936.69
-5,863,950
230,139.23
3/31/2021 - 9/10/2001
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CIPLA.NS Cipla Limited
1,515.20
+1.26%
SUNPHARMA.NS Sun Pharmaceutical Industries Limited
1,751.50
+3.45%
GLENMARK.NS Glenmark Pharmaceuticals Limited
1,342.40
-1.06%
ZYDUSLIFE.NS Zydus Lifesciences Limited
831.55
+1.15%
DRREDDY.NS Dr. Reddy's Laboratories Limited
1,163.60
+0.45%
AUROPHARMA.NS Aurobindo Pharma Limited
1,171.60
+3.37%
LAURUSLABS.NS Laurus Labs Limited
628.05
+0.18%
TORNTPHARM.NS Torrent Pharmaceuticals Limited
3,254.80
+1.00%
NEULANDLAB.NS Neuland Laboratories Limited
12,821.00
+0.56%
WOCKPHARMA.NS Wockhardt Limited
1,413.80
+1.54%